The Exchange has sought clarification from Nectar Lifesciences Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
NECLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
NSE has asked Nectar Lifesciences to clarify under SEBI's Listing Regulations why the financial results filed for the quarter ended 30 September 2025 were not submitted in the format prescribed by SEBI. The company has not yet responded, and its reply is awaited. This is a procedural query from the exchange rather than a punitive action. Investors should watch for the company's clarification and any revised financial submission.
This is a routine format-related query and not a penalty or investigation, so the immediate impact on shareholders is likely limited. However, a delayed or unsatisfactory response could attract further regulatory attention or penalties.